drugset

drugset / Trial / NCT00281541

A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma

NCT00281541 ↗

Phase 2 Completed 29 enrolled Astellas Pharma Inc Astellas Pharma US, Inc. · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

A study with YM155 for the treatment of unresectable stage III or metastatic stage IV melanoma.

Timeline

Start: 2005-11
Primary completion: —
Completion: 2007-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SEPANTRONIUM	Small molecule	—	—

Indications